
    
      This study is an open-label single site, randomized single dose study in 80 healthy Japanese
      male volunteers. The study consists of Period I to Period III, a total of 3 periods. In
      Period I, E2022 patches will be secured with seal. In Period II, single dose of E2022 5 mg
      tablet will be administered. In Period III, E2022 patches will be applied without seal. The
      features of the 5 patches will be evaluated in this study.
    
  